Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1909-1917

  Khong, Tiffany ^a   Spencer, Andrew ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BORTEZOMIB; BREAKPOINT CLUSTER REGION PROTEIN; CHAPERONE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE B; PROTEIN P53; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; BORONIC ACIDS; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; G1 PHASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MAP KINASE KINASE KINASES; MULTIPLE MYELOMA; PYRAZINES; PYRIDONES; PYRIMIDINES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 80053948169     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0174     Document Type: Article

References (47)

1. Balakumaran A, Robey PG, Fedarko N, Landgren O. Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn 2010;10:465-80.
2. Ritossa F. A new puffing pattern induced by temperature shock and DNP in drosophila. Cellular and Mol Life Sci 1962;18:571-3.
3. Lemeaux PG, Herendeen SL, Bloch PL, Neihardt FC. Transient rates of synthesis of individual polypeptides in E. coli following temperature shifts. Cell 1978;13:427-34.
4. Miller MJ, Xuong NH, Geiduschek EP. A response of protein synthesis to temperature shift in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 1979;76:5222-5. (Pubitemid 10236111)
5. Barnett TM, Altschuler C, McDaniel D, Mascarents JP. Heat shock induced proteins in plant cells. Dev Genet 1980;1:331-40.
6. Hightower LE, White FP. Cellular responses to stress: comparison of a family of 71-73-kilodalton proteins rapidly synthesized in rat tissue slices and canavanine-treated cells in culture. J Cell Physiol 1981; 108:261-75. (Pubitemid 11022652)
7. Smith HS, Pardee AB. Accumulation of a protein required for division during the cell cycle of Escherichia coli. J Bacteriol 1970;101:901-9.
8. Fink K, Zeuthen E. Heat shock proteins in Tetrahymena studied under growth conditions. Exp Cell Res 1980;128:23-30. (Pubitemid 11195191)
9. Ashburner M, Bonner JJ. The induction of gene activity in drosophilia by heat shock. Cell 1979;17:241-54. (Pubitemid 9230305)
10. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 1994;54:4952-7. (Pubitemid 24289427)
11. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99. (Pubitemid 39149859)
12. Garrido C, Gurbuxani S, Ravagnan L, Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun 2001;286:433-42. (Pubitemid 32912965)
13. Bansal GS, Norton PM, Latchman DS. The 90-kDa heat shock protein protects mammalian cells from thermal stress but not from viral infection. Exp Cell Res 1991;195:303-6. (Pubitemid 121006327)
14. Zurawska A, Urbanski J, Matuliene J, Baraniak J, Klejman MP, Filipek S, et al. Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo. Biochim Biophys Acta 2010;1803:575-83.
15. Schwock J, Pham NA, Cao MP, Hedley DW. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol 2008;61:669-81.
16. Muchemwa FC, Nakatsura T, Fukushima S, Nishimura Y, Kageshita T, Ihn H. Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. Melanoma Res 2008;18:166-71. (Pubitemid 351684661)
17. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15:9-14.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Monaghan K, Spencer A. The role of the bone marrow microenvironment in multiple myeloma. Asia-Pacific Journal of Oncology and Hematology 2010;2:49-56.
20. Chatterjee M, Jain S, Stühmer T, Andrulis M, Ungethüm U, Kuban RJ, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007;109:720-8. (Pubitemid 46105974)
21. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endo-Rel Cancer 2006;13:S125-35. (Pubitemid 46219254)
22. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74. (Pubitemid 34028664)
23. Belardo G, Piva R, Santoro MG. Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells. Leukemia 2010;24:187-96.
24. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000;96:1655-69. (Pubitemid 30661043)
25. Sacks DB. The role of scaffold proteins in MEK/ERK signalling. Biochem Soc Trans 2006;34:833-6. (Pubitemid 44796432)
26. Modi S, Stopeck AT, Linden HM, Solit DB, Chandarlapaty S, Rosen N, et al. HSP90 nhibition is effective in breast cancer: a phase 2 trial of tanespimycin (17AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011;17:5132-9.
27. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008;14:7940-6.
28. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61. (Pubitemid 46211321)
29. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60.
30. Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 2010;28:1520-6.
31. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543-6. (Pubitemid 44273031)
32. Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008;22:1410-8. (Pubitemid 352006085)
33. Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, et al. Synergistic activity of imatinib and 17-AAG in imatinibresistant CML cells overexpressing BCR-ABL-Inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005;19:1198-206. (Pubitemid 40946004)
34. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76. (Pubitemid 40223701)
35. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, et al. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 2003;102:1824-32. (Pubitemid 37022579)
36. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: inhibitors in clinical trials. J Med Chem 2010;53:3-17.
37. Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol 2010;150:438-45.
38. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010;150:428-37.
39. Yong K, Orlowski R, Davies F, Williams C, Cole C, Cavet J, et al. A phase 1/2 study of KW-2478 in combination with bortezomib in subjects with relapsed and/or refractory multiple myeloma: interim results from phase 1. 13th International Myeloma Workshop 2011 May 3-6, Abstract #P-169.
40. Khong T, Sharkey J, Spencer A. The effect of azacytidine on interleukin- 6 signalling and nuclear factor-kappa B activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 2008;93:860-9. (Pubitemid 351821722)
41. Sharkey J, Khong T, Spencer A. PKC412 demonstrates JNK-dependent against human multiple myeloma cells. Blood 2007;109:1712-9. (Pubitemid 46239606)
42. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-100. (Pubitemid 43156310)
43. Santarosa M, Favaro D, Quaia M, Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997;33:873-7. (Pubitemid 27287038)
44. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA. Clinical and biological significance of HSP89 alpha in human breast cancer. Int J Cancer 1992;50:409-15.
45. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003;102:3379-86. (Pubitemid 37314781)
46. Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, Broude EV, et al. Pharmacological induction of Hsp70 protects apoptosisprone cells from doxorubicin:comparison with caspase-inhibitorand cyclin-arrest-mediated cytoprotection. Cell Death Differ 2006;13:1434-41. (Pubitemid 44210347)
47. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp 27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007;6:299-308. (Pubitemid 46206694)